MARTINSRIED, Germany, Feb. 26, 2009 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment; TecDAX) today announced its financial results according to International Financial Reporting Standards (IFRS) for the three-months’ period and financial year ending December 31, 2008. The Company achieved Group revenues of EUR 71.6 million (2007: EUR 62.0 million) and more than doubled its operating profit to EUR 16.4 million (2007: EUR 7.0 million). The Research Antibodies segment AbD made the all-important transition to profitability in 2008. Group net profit after taxes increased to EUR 13.2 million (2007: EUR 11.5 million). At the end of the year 2008 MorphoSys’s cash position amounted to EUR 137.9 million (2007: EUR 106.9 million).
